Oxaliplatin- or irinotecan-based combination therapy versus 5-fluorouracil/leucovorin alone in the treatment of advanced colon cancer patients age 66 and older: An analysis using SEER-Medicare data.

Hsiao, FY; Mullins, C. Daniel; Pandya, N. B.; Onukwugha, E.; Seal, Brian; Hanna, N.

doi:10.1200/jco.2010.28.15_suppl.3613

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A SEER-Medicare based study also evaluated the use of several regimens in 8,294 patients >65 years receiving adjuvant therapy for stage III colon cancer. 18 The analysis included patients treated with 5-FU/LV alone (n = 7,726), oxaliplatin-based therapy (n = 816), and irinotecan-based therapy (n = 382). After adjusting for multiple factors, oxaliplatin-based therapy was associated with improved overall survival (HR: 0.566; 95% CI: 0.370–0.866; P = 0.0087) and colorectal cancer-specific survival (HR: 0.385; 95% CI: 0.208–0.712; P = 0.0023) when compared to 5-FU/LV alone.…”

Section: Colorectal Cancermentioning

confidence: 99%

Systemic Therapy for Elderly Patients with Gastrointestinal Cancer

Hubbard

Grothey

Sargent

2011

Clin Med Insights Oncol

View full text Add to dashboard Cite

The majority of patients with gastrointestinal cancers are over the age of 65. This age group comprises the minority of the patients enrolled in clinical trials, and it is unknown whether older patients achieve similar results as younger patients in terms of survival benefit and tolerability. In addition, there are few studies specifically designed for patients over 65 years. Subset analyses of individual trials and studies using pooled patient data from multiple trials provide some understanding on outcomes in older patients with gastrointestinal cancers. This article reviews the evidence on chemotherapeutic regimens in the elderly with colorectal, pancreatic, and gastroesophageal cancers, and discusses a practical approach to provide the best outcomes for older patients.

show abstract

Section: Colorectal Cancermentioning

confidence: 99%